Skip to main content

FDA Approvals

Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease

Jakafi a New Treatment Option for Chronic Graft-versus-Host Disease

Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-versus-Host Disease

Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation

Loretta Fala

Ukoniq (Umbralisib) FDA Approved for Adults with Relapsed or Refractory Marginal-Zone Lymphoma or Follicular Lymphoman

Loretta Fala

Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer

Loretta Fala

Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma

Loretta Fala

Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

Loretta Fala

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO, Oncology

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

Cholangiocarcinoma, FDA Approvals, Conference Highlights ASCO, Oncology

Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

Page 11 of 53
Results 101 - 110 of 527